Rani Therapeutics Holdings RANI
NASDAQ RANI
$0.84 +0.02 (+2.51%)
At close: Sep 11, 2026 · 4:00 PM EDT

Rani Therapeutics Holdings (RANI) Total Non-Current Liabilities (2020 - 2021)

Rani Therapeutics Holdings (RANI) posted Total Non-Current Liabilities of $2.6 million for Q4 2021, down 49.71% on a QoQ basis from $5.2 million in Q3 2021, and down 65.8% year-over-year from $7.7 million in Q4 2020.

Analysis

Rani Therapeutics Holdings (RANI) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends

Rani Therapeutics Holdings has reported Total Non-Current Liabilities for 2 years, with the latest figure at $2.6 million in Q4 2021.

  • On a quarterly basis, Total Non-Current Liabilities fell 65.8% year-over-year to $2.6 million in Q4 2021; TTM through Dec 2021 was $2.6 million, a 65.8% decrease from a year earlier, with the FY2021 full-year figure at $2.6 million, down 65.8% from the prior year.
  • Total Non-Current Liabilities was $2.6 million for Q4 2021 at Rani Therapeutics Holdings, down from $5.2 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $9.4 million in Q2 2021, with the low at $2.6 million in Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 40.00 Mn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 4.20 Bn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 378.37 Mn
10 Rani Therapeutics Holdings 157.97 Mn 157.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 2.64 Mn
Sep 30, 2021 5.25 Mn
Jun 30, 2021 9.36 Mn
Dec 31, 2020 7.72 Mn